Clinical Study of Targeting CD123 Chimeric Antigen Receptor Natural Killer Cells (CAR-NK) in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Chongqing Precision Biotech Co., Ltd is advancing a promising CAR-NK cell therapy targeting CD123 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The market for AML therapies is significant, with a growing demand for innovative treatments due to high relapse rates and limited options for refractory cases. The competitive landscape includes established therapies such as chemotherapy and emerging CAR-T cell therapies. Successful outcomes in this trial could position Chongqing Precision Biotech favorably against competitors, potentially leading to strategic partnerships or acquisition interest. Diligence considerations should focus on regulatory pathways, manufacturing capabilities, and the scalability of CAR-NK cell production.
Indication: Acute Myeloid Leukemia
Modality: protein therapy
Target: CD123 Chimeric Antigen Receptor (CAR) on Natural Killer (NK) Cells
Sponsor: Chongqing Precision Biotech Co., Ltd
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD123 Chimeric Antigen Receptor (CAR) on Natural Killer (NK) Cells
View original source fields
Condition raw: Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Relapse Leukemia, Refractory Leukemia
Condition normalized: Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Relapse Leukemia, Refractory Leukemia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD123 Chimeric Antigen Receptor (CAR) on Natural Killer (NK) Cells
Target normalized: CD123 Chimeric Antigen Receptor (CAR) on Natural Killer (NK) Cells